Caldera and Vidya secure $478M via reverse mergers to go public
Caldera Therapeutics, a U.S. bispecific antibody biotech, announced a reverse merger with Nasdaq-listed Synlogic to become a public company.
The deal includes a $278 million private placement from investors such as Bain Capital Life Sciences, TCGX, Atlas Venture, venBio Partners and Blackstone Multi‑Asset Investing, giving them 34.9% of the combined entity while Caldera’s existing backers retain 62.8%.
Vidya Therapeutics completed a separate reverse merger, and together the two companies raised $478 million to advance immunology and inflammation programs.
These transactions highlight that reverse mergers remain a viable path for venture‑backed biotechs to access public markets after setbacks like Synlogic’s failed Phase 3 trial.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that